Dr. Dion Khodagholy Joins Bioelectronic Medicine Company Panaxium SAS as Scientific Advisor

Groundbreaking brain researcher and Columbia University Assistant Professor is developing novel electronic devices that allow efficient interaction with biological substrates.

Aix-en-Provence, FRANCE, and Toronto, CANADA, December 5, 2017. Bioelectronic medicine company Panaxium SAS today announced that Columbia University Assistant Professor Dion Khodagholy will join the company as Scientific Advisor.

Bioelectronic medicine is an emerging scientific field that aims to tackle many debilitating and degenerative medical conditions and injuries by leveraging the newest bioelectronics and building imperceptible devices at the microscale dimensions of individual cells. There is significant potential to treat a wide range of diseases such as Traumatic Brain Injuries, Parkinson’s, Alzheimer’s, and even peripheral nerve damage.

Dr. Khodagholy’s research is focused on using the unique properties of new bioelectronic materials for the purpose of designing and developing novel electronic devices that will allow for vastly improved and highly efficient interaction with biological substrates, specifically for neural networks and the brain.  This process involves the design, characterization, and fabrication of high-performance biocompatible electronics that are able to acquire and analyze neural data. Ultimately, Dr. Khodagholy aspires that his research will translate these recent advancements into groundbreaking diagnostics and treatments for neuropsychiatric diseases.

Dr. Khodagholy joined Columbia Engineering in 2017, after completing a postdoctoral fellowship in systems neuroscience at New York University, Langone Medical Center. He received his PhD in 2012 and his MS in electrical engineering in 2009, both from the L'École Nationale Supérieure des Mines de Saint-Étienne in France,  and a Masters in engineering from the University of Birmingham, U.K, in 2008.  

Some of Dr. Khodagholy’s research related to a deeper understanding of how the human brain works, including memory formation as well as the necessary requirements for successful brain-machine interfaces, have received significant international scientific attention recently.

Dr. Brad Schmidt, CEO of Panaxium, says of Khodagholy joining the team, “Dion’s research in how these new bioelectronic materials will lead to advancements in diagnostics and treatments for neuropsychiatric diseases is truly groundbreaking. His subject matter expertise in the brain and its many mysteries makes him truly in a class by himself. I know that I can speak on behalf of our entire team of scientists when I say how truly thrilled we are that he has joined our team as Scientific Advisor.”

ABOUT PANAXIUM
Founded in 2016, Panaxium is a new and rapidly-growing bioelectronic medicine company aiming to fundamentally change the way disease is treated. The company is comprised of a multidisciplinary team of internationally-renowned scientists, including world experts in organic bioelectronics and leaders in the fields of chemistry, materials science, electrical engineering, systems design, electronic engineering, data science, biology, biochemistry, and nanotechnology. Together they are working to solve some of the most difficult and important problems in medicine.


For further information, please visit http://www.panaxium.com

Back